MedTrace Logo

Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

NCT06039124 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2023-09-15

No results posted yet for this study

Summary

Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT.

We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment.

We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

Conditions

  • Hemorrhagic Hereditary Telangiectasia
  • HHT

Interventions

OTHER

bevacizumab treatment

Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Sophie DUPUIS-GIROD, PhD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-01-01
Completion
2022-08-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06039124 on ClinicalTrials.gov